FOLH1 and prostate adenocarcinoma: We found that prostate adenocarcinoma had among the highest differences in expression of FOLH1 relative to its matched normal tissue, consistent with past investigations involving the use of PSMA-targeting theranostics and their successful implementation within the disease [6].